Approximately one in 30 NIH-funded clinical trials—and more than 74,000 trial participants—were affected by grant funding disruptions caused by the Trump administration, according to an analysis in JAMA Internal Medicine.
An NIH employee who has been publicly critical of the Trump administration’s health policies said she was placed on “nondisciplinary” administrative leave when she returned to work Nov. 13 after the government reopened.
Natalie Phelps, a 43-year-old mother of two, died Nov. 9 from colorectal cancer.
FDA Commissioner Marty Makary and Vinay Prasad, FDA’s chief medical and scientific officer and director of the agency’s Center for Biologics Evaluation and Research, jointly published a letter in The New England Journal of Medicine spelling out the rationale for FDA’s new “plausible mechanism pathway,” aimed at getting bespoke therapies to market without the need for a randomized controlled trial.
On the evening of Nov. 12, President Donald Trump signed a continuing resolution that officially ended the 43-day-long U.S. government shutdown that began on Oct. 1.
Cornell University has come to an agreement with the Trump administration that will unfreeze the university’s more than $250 million in interrupted federal research funding and “protect Cornell’s students from violations of federal civil rights laws, including from discrimination based on race, sex, or national origin, and promote America’s hardworking farming and rural communities” following accusations of antisemitism and discrimination in admissions.
CMS announced a new drug payment model called the GENErating cost Reductions for U.S. Medicaid (GENEROUS) Model that the agency plans to pilot next year.
The U.S. Preventative Services Task Force has postponed its November meeting due to the federal government shutdown.
FDA announced six additional awardees under the Commissioner’s National Priority Voucher pilot program, which aims to accelerate review time for applications that are deemed to be advancing U.S. “national priorities” (The Cancer Letter, Oct. 24, June 20, 2025).
The American Academy of Pediatrics does not recommend the routine use of leucovorin (folinic acid) for autistic children, according to the interim guidance issued by the physician group Oct. 31.
